Your browser doesn't support javascript.
loading
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Deming, Dustin A; Cavalcante, Ludmila L; Lubner, Sam J; Mulkerin, Daniel L; LoConte, Noelle K; Eickhoff, Jens C; Kolesar, Jill M; Fioravanti, Suzanne; Greten, Tim F; Compton, Kathryn; Doyle, Austin G; Wilding, George; Duffy, Austin; Liu, Glenn.
Afiliação
  • Deming DA; University of Wisconsin-Madison Carbone Cancer Center, 600 Highland Avenue, K6/544 CSC, Madison, WI, 53792, USA. ddeming@medicine.wisc.edu.
  • Cavalcante LL; University of Wisconsin-Madison Carbone Cancer Center, 600 Highland Avenue, K6/544 CSC, Madison, WI, 53792, USA.
  • Lubner SJ; University of Wisconsin-Madison Carbone Cancer Center, 600 Highland Avenue, K6/544 CSC, Madison, WI, 53792, USA.
  • Mulkerin DL; University of Wisconsin-Madison Carbone Cancer Center, 600 Highland Avenue, K6/544 CSC, Madison, WI, 53792, USA.
  • LoConte NK; University of Wisconsin-Madison Carbone Cancer Center, 600 Highland Avenue, K6/544 CSC, Madison, WI, 53792, USA.
  • Eickhoff JC; University of Wisconsin-Madison Carbone Cancer Center, 600 Highland Avenue, K6/544 CSC, Madison, WI, 53792, USA.
  • Kolesar JM; University of Wisconsin-Madison Carbone Cancer Center, 600 Highland Avenue, K6/544 CSC, Madison, WI, 53792, USA.
  • Fioravanti S; National Cancer Institute/Medical Oncology Branch, Bethesda, MD, USA.
  • Greten TF; National Cancer Institute/Medical Oncology Branch, Bethesda, MD, USA.
  • Compton K; National Cancer Institute/Medical Oncology Branch, Bethesda, MD, USA.
  • Doyle AG; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
  • Wilding G; University of Wisconsin-Madison Carbone Cancer Center, 600 Highland Avenue, K6/544 CSC, Madison, WI, 53792, USA.
  • Duffy A; National Cancer Institute/Medical Oncology Branch, Bethesda, MD, USA.
  • Liu G; University of Wisconsin-Madison Carbone Cancer Center, 600 Highland Avenue, K6/544 CSC, Madison, WI, 53792, USA.
Invest New Drugs ; 34(2): 168-75, 2016 Apr.
Article em En | MEDLINE | ID: mdl-26666244
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benzimidazóis / Neoplasias Colorretais / Proteínas Proto-Oncogênicas p21(ras) / Quinases de Proteína Quinase Ativadas por Mitógeno / Inibidores de Proteínas Quinases / Cetuximab / Mutação Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benzimidazóis / Neoplasias Colorretais / Proteínas Proto-Oncogênicas p21(ras) / Quinases de Proteína Quinase Ativadas por Mitógeno / Inibidores de Proteínas Quinases / Cetuximab / Mutação Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos